Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
Yuchuan Wang, Wenhao Yang, Chia‐Shin Yang, Mei‐Hui Hou, Chia-Ling Tsai, Yi-Zhen Chou, Mien‐Chie Hung, Yeh Chen
Abstract
covalently linked through forming a hemithioacetal group and releasing a sulfonic acid group. Because GC376 is already known as a broad-spectrum antiviral medication and successfully used in animal, it will be a suitable candidate for anti-COVID-19 treatment.
Topics & Concepts
CoronavirusVirologyProteaseMiddle East respiratory syndrome coronavirusIsothermal titration calorimetryVirusViral replicationChemistryBiologyCoronavirus disease 2019 (COVID-19)MedicineEnzymeBiochemistryPathologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsViral gastroenteritis research and epidemiology